Cellectis ADR
CLLSHealthcare·Biotechnology·France·Micro·NASD·Nov 13 • 7:02 AM ET
1.15-0.18 (-13.46%)
2026-11-13 13:12 CET
Market cap
$83.22M
Revenue, TTM
56.42 USD m
Net income, TTM
-65.33 USD m
Free cash flow, TTM
-44.18 USD m
EPS diluted, TTM
-0.65
Price
CLLS against its 20, 50 and 200-day averagesPatternshover a marker to name it
78.9% under the 52-week high of 5.45 on 11 Dec 2025. 52-week low 0.88 on 19 Oct 2026. Last 15 sessions, 64.3% high to low
Volume 0.97× normal · the line is the 50-bar volume average
Setup. RS line 1
CANSLIM 0 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
CLLS52-week range, 6% of the way up
0.885.45
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.
| Employees | 229 |
|---|---|
| IPO | Mar 25, 2015 |
| Beta | 3.16 |
| ATR, 14d | 0.14 |
| Rel volume | 0.97 |
| Short float | 0.48% |
| Insider own | 3.93% |
| Inst own | 13.20% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $83.22M |
| Enterprise Value | 20.65M |
| Income | -65.33M |
| Sales | 56.42M |
| Book / share | 0.41 |
| Cash / share | 2.31 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 229 |
| IPO | Mar 25, 2015 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 1.47 |
| Price / book | 2.82 |
| Price / cash | 0.50 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 0.37 |
| Quick Ratio | 1.37 |
| Current Ratio | 1.37 |
| Debt / equity | 2.54 |
| Long-term debt / equity | 2.19 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.65 |
|---|---|
| Earnings next year | -0.67 |
| Earnings next quarter | -0.20 |
| Earnings this year | -19.90% |
| Earnings next year | 17.01% |
| Earnings growth, 5 years | -26.03% |
| Past earnings growth | 33.81% 18.84% |
| Past sales growth | 56.25% -0.34% |
| Earnings vs last year | -13.99% |
| Sales vs last year | -0.11% |
| Earnings vs last quarter | 9.72% |
| Sales vs last quarter | -69.19% |
| Earnings | Nov 13 BMO |
| Surprise | -238.89% -75.89% |
Ownership
| Insiders own | 3.93% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 13.20% |
| Institution trades | 0.20% |
| Return on assets | -21.03% |
| Return on equity | -94.56% |
| Return on capital | -49.84% |
| Gross Margin | 66.25% |
| Operating margin | -116.10% |
| Profit Margin | -115.79% |
| 20-day average | 5.30% |
| 50-day average | -20.45% |
| 200-day average | -60.59% |
Technical
| Shares out | 100.70M |
|---|---|
| Shares floating | 69.48M |
| Short / float | 0.48% |
| Short ratio | 2.99 |
| Short interest | 0.33M |
| 52-week high | 5.45 -78.9% |
| 52-week low | 0.88 +30.6% |
| Volatility | 11.99% 10.81% |
| Average range | 0.14 |
| Strength index | 46.28 |
| Market sensitivity | 3.16 |
| Relative volume | 0.97 |
| Avg Volume | 111.37K |
| Volume | 5,383 |
Performance
| Perf Week | 7.52% |
|---|---|
| Perf Month | 4.12% |
| Perf Quarter | -63.01% |
| Perf Half Y | -70.65% |
| Perf YTD | -76.23% |
| Perf Year | -67.77% |
| Perf 3Y | -54.35% |
| Perf 5Y | -89.11% |
| Perf 10Y | -93.99% |
| Recommendation | 2.29 |
| Target Price | 5.00 |
| Prev Close | 1.33 |
| Price | 1.15 |
| Change % | -13.50% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 16, 2026 | Downgrade | Barclays | Overweight → Underweight | $1.30 | +13.0% |
| Sep 15, 2026 | Downgrade | Citizens | Mkt Outperform → Mkt Perform | ||
| May 28, 2026 | Initiated | Barclays | Overweight | $9 | +682.3% |
| Feb 17, 2026 | Resumed | Jefferies | Buy | $7 | +508.4% |
| Mar 17, 2023 | Initiated | Bryan Garnier | Buy | $6 | +421.5% |
| May 18, 2022 | Upgrade | Robert W. Baird | Neutral → Outperform | $10 | +769.2% |
| Jan 06, 2022 | Downgrade | Wells Fargo | Overweight → Equal Weight | $39 → $16 | +1,290.7% |
| Nov 30, 2021 | Initiated | JMP Securities | Mkt Outperform | $20 | +1,638.4% |
| Nov 08, 2021 | Downgrade | William Blair | Outperform → Mkt Perform | ||
| Oct 08, 2021 | Downgrade | Robert W. Baird | Outperform → Neutral | $39 → $10 | +769.2% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| CRBU | Caribou Biosciences Inc | 41.18M |
| ALLO | Allogene Therapeutics Inc | 301.46M |
| ATRA | Atara Biotherapeutics Inc | 80.79M |
| CRSP | CRISPR Therapeutics AG | 4.21B |
| DTIL | Precision Biosciences Inc | 224.60M |
| IPSC | Century Therapeutics Inc | 295.15M |
| SANA | Sana Biotechnology Inc | 617.46M |
| FATE | Fate Therapeutics Inc | 162.90M |
| NKTX | Nkarta Inc | 90.71M |
| AUTL | Autolus Therapeutics plc ADR | 316.94M |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
News
latest 14 of 200- Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire) -13.50%
- Cellectis to Report Third Quarter Financial Results on November 12, 2026 (GlobeNewswire)
- Monthly information on share capital and company voting rights (GlobeNewswire) +7.34% -11.97%
- Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 (GlobeNewswire) +8.64%
- Monthly information on share capital and company voting rights (GlobeNewswire)
- Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls (The Fly) -14.60%
- Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls (The Fly) -12.02%
- CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
- Cellectis Announces In Vivo Gene Editing Transformation, Exits Lasme-cel and Eti-cel Development (InvestorsHub) -40.97%
- Cellectis quits CAR-Ts and pivots to in vivo gene editing (BioPharma Dive)
- Cellectis quits CAR-T and pivots to in vivo gene editing (BioPharma Dive)
- Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company (GlobeNewswire)
- Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update (GlobeNewswire)
- Monthly information on share capital and company voting rights (GlobeNewswire)
Quarterly earnings
2026Q3 EPS -0.610 missed -0.180, from 0.010 a year earlier. Sales 3.76 missed 15.61, from 37.16 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-13 08:30 | -0.610 | -0.180 | -0.610 | 3.76 | 15.61 | EPS +238.9% · sales -75.9% | vs 2025Q3, year-ago quarter · EPS -6200.0% · sales -89.9% | 5 EPS · 4 sales | Open -17.29% vs SPY -0.14%. Close -13.50% vs SPY +0.31% |
| 2026Q2ended 2026-06-30 | 2026-08-06 16:30 | -0.220 | -0.263 | -0.220 | 6.90 | 11.05 | EPS -16.3% · sales -37.5% | vs 2025Q2, year-ago quarter · EPS -8.3% · sales -62.1% | 6 EPS · 4 sales | Open +0.37% vs SPY +0.32%. Close +5.39% vs SPY +0.61% |
| 2026Q1ended 2026-03-31 | 2026-05-11 16:30 | -0.180 | -0.258 | -0.177 | 7.55 | 11.04 | EPS -30.3% · sales -31.6% | vs 2025Q1, year-ago quarter · EPS 0.0% · sales -37.3% | 6 | Open -2.26% vs SPY -0.33%. Close -0.50% vs SPY -0.15% |
| 2025Q4ended 2025-12-31 | 2026-03-19 16:30 | -0.260 | -0.203 | -0.262 | 12.16 | 13.39 | EPS +27.9% · sales -9.2% | vs 2024Q4, year-ago quarter · EPS +52.9% · sales -63.4% | 6 EPS · 7 sales | Open -3.16% vs SPY -0.50%. Close -4.02% vs SPY -1.70% |
| 2025Q3ended 2025-09-30 | 2025-11-07 16:30 | 0.010 | -0.232 | 0.006 | 37.16 | 9.55 | EPS -104.3% · sales +289.1% | vs 2024Q3, year-ago quarter · EPS -104.3% · sales +105.9% | 6 | Open +12.54% vs SPY +0.93%. Close +11.29% vs SPY +1.56% |
| 2025Q2ended 2025-06-30 | 2025-08-04 16:30 | -0.240 | -0.214 | -0.240 | 18.19 | 11.23 | EPS +12.1% · sales +62.1% | vs 2024Q2, year-ago quarter · EPS -14.3% · sales +91.4% | 5 | Open +1.99% vs SPY +0.10%. Close -16.23% vs SPY -0.51% |
| 2025Q1ended 2025-03-31 | 2025-05-12 16:30 | -0.180 | -0.154 | -0.181 | 12.03 | 13.83 | EPS +16.9% · sales -13.0% | vs 2024Q1, year-ago quarter · EPS -325.0% · sales +85.1% | 5 EPS · 4 sales | Open -5.96% vs SPY +0.07%. Close -6.62% vs SPY +0.66% |
| 2024Q4ended 2024-12-31 | 2025-03-13 16:30 | -0.170 | -0.185 | 0.082 | 33.22 | 9.86 | EPS -8.1% · sales +236.9% | vs 2023Q4, year-ago quarter · EPS -73.4% · sales +1569.1% | 6 EPS · 5 sales | Open +8.53% vs SPY +0.85%. Close -3.88% vs SPY +2.07% |
| 2024Q3ended 2024-09-30 | 2024-11-04 16:30 | -0.230 | -0.203 | -0.231 | 18.05 | 9.77 | EPS +13.2% · sales +84.7% | vs 2023Q3, year-ago quarter · EPS -25.8% · sales +997.9% | 6 EPS · 5 sales | Open +7.95% vs SPY +0.16%. Close +1.14% vs SPY +1.21% |
| 2024Q2ended 2024-06-30 | 2024-08-06 16:30 | -0.280 | -0.287 | -0.252 | 9.50 | 3.70 | EPS -2.3% · sales +156.9% | vs 2023Q2, year-ago quarter · EPS +47.4% · sales +375.0% | 7 EPS · 6 sales | Open -0.97% vs SPY +1.21%. Close -0.48% vs SPY -0.67% |
| 2024Q1ended 2024-03-31 | 2024-05-28 16:30 | 0.080 | -0.330 | 0.055 | 6.50 | 3.70 | EPS -124.2% · sales +75.7% | vs 2023Q1, year-ago quarter · EPS -113.8% · sales +82.6% | 5 EPS · 4 sales | Open -7.91% vs SPY -0.78%. Close -2.16% vs SPY -0.70% |
| 2023Q4ended 2023-12-31 | 2024-04-29 16:30 | -0.640 | -0.195 | -0.602 | 1.99 | 1.80 | EPS +228.2% · sales +10.6% | vs 2022Q4, year-ago quarter · EPS +8.5% · sales -88.5% | 3 EPS · 1 sales | Open -1.56% vs SPY -0.29%. Close 0.00% vs SPY -1.58% |
| 2023Q3ended 2023-09-30 | 2023-11-06 16:30 | -0.310 | -0.418 | -0.313 | 1.64 | 3.38 | EPS -25.8% · sales -51.4% | vs 2022Q3, year-ago quarter · EPS -50.8% · sales -14.4% | 8 | - |
| 2023Q2ended 2023-06-30 | 2023-08-03 16:30 | -0.190 | -0.438 | -0.191 | 2.00 | 4.48 | EPS -56.7% · sales -55.3% | vs 2022Q2, year-ago quarter · EPS -54.8% · sales -27.6% | 7 EPS · 6 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-04 16:30 | -0.580 | -0.481 | -0.587 | 3.56 | 5.99 | EPS +20.5% · sales -40.6% | vs 2022Q1, year-ago quarter · EPS -17.1% · sales -7.1% | 7 EPS · 6 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-08 16:30 | -0.590 | -0.596 | -0.593 | 17.32 | 18.58 | EPS -1.0% · sales -6.8% | vs 2021Q4, year-ago quarter · EPS +7.3% · sales +26.8% | 9 EPS · 7 sales | - |
Annual earnings
2025FY EPS -0.671 beat -0.757, from -0.410 a year earlier. Sales 79.60 beat 77.35, from 49.22 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.630 | - | - | 161.31 | - |
| 2029FYestimate | - | -1.050 | - | - | 92.73 | - |
| 2028FYestimate | - | -1.341 | - | - | 73.48 | - |
| 2027FYestimate | - | -0.667 | - | - | 85.32 | - |
| 2026FYestimate | - | -0.803 | - | - | 53.56 | - |
| 2025FY | -0.671 | -0.757 | -0.671 | 79.60 | 77.35 | - |
| 2024FY | -0.410 | -0.633 | -0.405 | 49.22 | 41.51 | - |
| 2023FY | -1.770 | -1.184 | -1.775 | 9.19 | 30.44 | - |
| 2022FY | -2.330 | -2.300 | -2.332 | 25.73 | 32.85 | - |
| 2021FY | -2.550 | -3.063 | -2.544 | 67.07 | 61.20 | - |
| 2020FY | -1.910 | -2.189 | -1.920 | 82.46 | 62.04 | - |
| 2019FY | -2.410 | -2.471 | -2.405 | 22.99 | 22.63 | - |
| 2018FY | -1.930 | -2.451 | -1.928 | 21.43 | 25.89 | - |
| 2017FY | -2.780 | -2.657 | -2.813 | 33.72 | 35.70 | - |
| 2016FY | -1.820 | -1.805 | - | 53.97 | 49.53 | - |
| 2015FY | -0.620 | -0.889 | - | 61.25 | 33.03 | - |
| 2014FY | -0.074 | - | 0.036 | 31.95 | - | - |
| 2013FY | -2.852 | -1.236 | - | 10.61 | 16.78 | - |
| 2012FY | -1.147 | -0.798 | - | 21.29 | 27.34 | - |
| 2011FY | -1.428 | -0.598 | -1.350 | 15.49 | 23.29 | - |
| 2010FY | -0.905 | -0.671 | -0.930 | 21.16 | 17.88 | - |
Quarterly results
2026Q2 revenue 5.22, from 16.95 a year earlier. Operating margin -487.55%, from -68.4% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026Q4 E -0.20 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026Q4 | E | per share | 2026-11-13 | -0.20 | 0.0% |
| 2026Q4 | R | per share | 2026-11-13 | -0.20 | 0.0% |
| 2026Q4 | S | per share | 2026-11-13 | 21.59 | 0.0% |
| 2026FY | S | per share | 2026-11-03 | 53.56 | 0.0% |
| 2026FY | E | per share | 2026-10-25 | -0.80 | 0.0% |
| 2026Q3 | E | per share | 2026-10-25 | -0.18 | 0.0% |
| 2026FY | R | per share | 2026-10-25 | -0.80 | 0.0% |
| 2026Q3 | R | per share | 2026-10-25 | -0.18 | 0.0% |
| 2026Q3 | S | per share | 2026-10-21 | 15.61 | 0.0% |
| 2026Q2 | E | per share | 2026-08-07 | -0.24 | -10.2% |
| 2026Q2 | R | per share | 2026-08-07 | -0.24 | -10.2% |
| 2026Q2 | S | per share | 2026-08-07 | 10.87 | -1.6% |
| 2026Q1 | E | per share | 2026-05-12 | -0.22 | -13.6% |
| 2026Q1 | R | per share | 2026-05-12 | -0.22 | -13.6% |
| 2026Q1 | S | per share | 2026-05-12 | 8.90 | -19.4% |
| 2025FY | E | per share | 2026-03-13 | -0.58 | 0.0% |
| 2025Q4 | E | per share | 2026-03-13 | -0.17 | 0.0% |
| 2025FY | R | per share | 2026-03-13 | -0.58 | 0.0% |
| 2025Q4 | R | per share | 2026-03-13 | -0.17 | 0.0% |
| 2025FY | S | per share | 2026-03-13 | 81.01 | 0.0% |
| 2025Q4 | S | per share | 2026-03-13 | 12.43 | 0.0% |
| 2025Q3 | S | per share | 2025-10-21 | 9.55 | 0.0% |
| 2025Q3 | E | per share | 2025-10-19 | -0.23 | 0.0% |
| 2025Q3 | R | per share | 2025-10-19 | -0.23 | 0.0% |
| 2025Q2 | E | per share | 2025-07-27 | -0.21 | 0.0% |
| 2025Q2 | R | per share | 2025-07-27 | -0.21 | 0.0% |
| 2025Q2 | S | per share | 2025-07-27 | 11.23 | 0.0% |
| 2025Q1 | E | per share | 2025-03-14 | -0.15 | -6.8% |
| 2024FY | R | per share | 2025-03-14 | -0.70 | +10.4% |
| 2024Q4 | R | per share | 2025-03-14 | -0.29 | +56.7% |
| 2025Q1 | R | per share | 2025-03-14 | -0.15 | -6.8% |
| 2025Q1 | S | per share | 2025-03-14 | 13.83 | +20.3% |
| 2024FY | S | per share | 2025-03-02 | 41.51 | 0.0% |
| 2024FY | E | per share | 2025-02-23 | -0.63 | +19.1% |
| 2024Q4 | E | per share | 2025-02-23 | -0.18 | +108.2% |
| 2024Q4 | S | per share | 2025-02-23 | 9.86 | -54.6% |
| 2024Q3 | E | per share | 2024-10-21 | -0.20 | 0.0% |
| 2024Q3 | R | per share | 2024-10-21 | -0.20 | 0.0% |
| 2024Q3 | S | per share | 2024-10-21 | 9.77 | 0.0% |
| 2024Q2 | E | per share | 2024-06-29 | -0.29 | 0.0% |
| 2024Q2 | R | per share | 2024-06-29 | -0.29 | 0.0% |
| 2024Q2 | S | per share | 2024-06-13 | 3.70 | +6.6% |
| 2024Q1 | E | per share | 2024-05-02 | -0.33 | +2.5% |
| 2024Q1 | R | per share | 2024-05-02 | -0.33 | +2.5% |
| 2024Q1 | S | per share | 2024-04-30 | 3.70 | +19.3% |
| 2023FY | E | per share | 2024-04-19 | -1.18 | +16.5% |
| 2023FY | R | per share | 2024-04-19 | -1.18 | +16.5% |
| 2023FY | S | per share | 2024-04-19 | 30.44 | -19.6% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -2.813 | -1.928 | -2.405 | -1.92 | -2.544 | -2.332 | -1.775 | -0.405 | -0.676 | -0.6502 | - |
| Sales USD millions | 25 | 13 | 15 | 74 | 30 | 19 | 1 | 41 | 73 | 56 | - |
| Shares million shares | 36 | 42 | 42 | 43 | 45 | 46 | 72 | 100 | 100 | - | 101 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.252 | -0.231 | 0.082 | -0.181 | -0.24 | 0.006 | -0.262 | -0.177 | -0.217 |
| Sales USD millions | 8 | 16 | 13 | 11 | 17 | 35 | 10 | 6 | 5 |
| Shares million shares | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 101 | 101 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 56.42 | 73.17+76.6% | 41.43+5351.3% | 0.76-96.0% | 19.18-36.7% | 30.30-59.3% | 74.44+390.1% | 15.19+19.4% | 12.72 |
| Cost of Goods Sold Incl. D&A | 19.04 | 20.12+1.4% | 19.84+3.1% | 19.25+3.9% | 18.52+16.0% | 15.97-56.3% | 36.52+220.6% | 11.39+315.7% | 2.74 |
| Gross Profit | 37.38 | 53.05+145.7% | 21.59 | -18.50-2903.0% | 0.66-95.4% | 14.32-62.2% | 37.92+897.9% | 3.80-61.9% | 9.98 |
| Selling, General and Administrative Excl. Other | 102.89 | 93.53+4.4% | 89.59+1.5% | 88.29-10.2% | 98.31-21.9% | 125.88-4.9% | 132.32-2.0% | 135.03+9.2% | 123.68 |
| Research and Development | 82.95 | 75.08+4.2% | 72.02-18.0% | 87.78-10.0% | 97.55-17.1% | 117.66+34.4% | 87.53-4.9% | 92.02+20.3% | 76.48 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - |
| Operating Income | -65.51 | -40.48 | -68.00 | -106.79 | -97.65 | -111.56 | -94.40 | -131.24 | -113.70 |
| Interest Expense | 8.41 | 8.13+8.7% | 7.48+16.1% | 6.44-60.6% | 16.34+274.8% | 4.36+19.5% | 3.65+23.3% | 2.96+311.1% | 0.72 |
| Unusual Expense | 7.48 | 14.32 | -11.62-156.4% | 20.60 | 0.00 | 0.00 | 0.00 | - | - |
| Net Income Before Taxes | -72.92 | -74.89 | -43.13 | -123.24 | -105.20 | -104.82 | -106.62 | -122.99 | -96.79 |
| Income Taxes | -7.59 | -7.09 | -6.44 | -6.22 | -6.46 | -8.23 | -8.49 | -7.80 | -8.55 |
| Consolidated Net Income | -65.33 | -67.80 | -36.70 | -117.02 | -98.74 | -96.60 | -98.13 | -115.19 | -88.24 |
| Net Income From Continuing Operations | -65.33 | -67.80 | -36.70 | -109.62 | -90.84 | -85.70 | -81.61 | -102.07 | -78.61 |
| Net Income | -65.33 | -67.80 | -36.70 | -101.22 | -106.20 | -114.02 | -81.61 | -102.07 | -78.61 |
| EPS (Recurring) per share | -0.60 | -0.58 | -0.50 | -1.52 | -2.33 | -2.54 | -1.92 | -2.40 | -1.93 |
| EPS (Basic, Before Extraordinaries) per share | -0.65 | -0.68 | -0.41 | -1.78 | -2.33 | -2.54 | -1.92 | -2.40 | -1.93 |
| EPS (Diluted) per share | -0.65 | -0.68 | -0.41 | -1.78 | -2.33 | -2.54 | -1.92 | -2.40 | -1.93 |
| EBITDA | -46.46 | -20.36 | -48.16 | -88.24 | -79.20 | -97.42 | -84.51 | -124.36 | -111.33 |
| Non-Operating Income (Expense) | 8.47 | -11.96-157.7% | 20.72+95.7% | 10.59+20.5% | 8.79-20.7% | 11.09 | -8.57-176.4% | 11.21-36.4% | 17.63 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 5.98 | 4.60+94.1% | 2.37-38.4% | 3.85-13.3% | 4.44-46.2% | 8.26-31.9% | 12.13-34.6% | 18.54-50.1% | 37.18 |
| Price To Sales Ratio ratio | 5.35 | 6.63 | 3.93 | 232.22 | 4.99 | 12.01 | 15.45 | 47.84 | 53.38 |
| Gross Margin % | 66.25 | 72.50 | 52.12 | -2,446.23 | 3.44 | 47.28 | 50.95 | 25.00 | 78.49 |
| Operating Margin % | -116.10 | -55.32 | -164.12 | -14,122.65 | -509.08 | -368.18 | -126.81 | -864.13 | -894.06 |
| Net Margin % | -115.79 | -92.66 | -88.57 | -13,385.30 | -553.64 | -376.30 | -109.64 | -672.09 | -618.12 |
| Shares Outstanding million shares | 100.70 | 100.34+0.2% | 100.09+39.5% | 71.75+57.1% | 45.68+0.4% | 45.48+6.3% | 42.78+0.7% | 42.47+0.1% | 42.43 |
| Market Capitalization | 96.19 | 96.19-25.9% | 129.77-41.3% | 220.99+131.4% | 95.50-74.1% | 369.26-67.9% | 1,149.76+58.2% | 726.67+3.7% | 701.06 |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5.22-69.2% | 5.80-45.6% | 10.39-17.7% | 35.01+115.4% | 16.95+110.6% | 10.66+135.8% | 12.63+4255.2% | 16.25+10733.3% |
| Cost of Goods Sold Incl. D&A | 4.41-13.2% | 4.55-7.7% | 5.10-11.9% | 4.99+5.5% | 5.08+7.6% | 4.93+8.1% | 5.79+7.4% | 4.73+2.6% |
| Gross Profit | 0.82-93.1% | 1.25-78.2% | 5.29-22.7% | 30.03+160.9% | 11.86+256.2% | 5.73 | 6.84 | 11.51 |
| Selling, General and Administrative Excl. Other | 26.27+12.0% | 28.35+30.5% | 24.12+21.6% | 24.16-0.8% | 23.45-14.1% | 21.72-4.8% | 19.83-23.5% | 24.35+27.6% |
| Research and Development | 20.89+11.9% | 23.09+32.9% | 19.62+27.7% | 19.34-19.1% | 18.67-20.5% | 17.37-22.0% | 15.36-40.3% | 23.90+27.1% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -25.45 | -27.10 | -18.83 | 5.87 | -11.59 | -15.99 | -12.99 | -12.83 |
| Interest Expense | 2.01-3.4% | 2.27+18.8% | 2.03+18.7% | 2.10-2.3% | 2.08+13.7% | 1.91+7.3% | 1.71-90.3% | 2.15+32.7% |
| Unusual Expense | -2.25-875.9% | -6.09 | 8.79 | 7.03+83.6% | 0.29-97.0% | -1.87 | -1.22 | 3.83 |
| Net Income Before Taxes | -23.44 | -19.56 | -28.53-658.3% | -1.40 | -25.58 | -19.48-666.3% | 5.11 | -25.00 |
| Income Taxes | -1.65 | -1.73 | -2.23 | -1.98 | -1.53 | -1.34 | -0.77 | -1.88 |
| Consolidated Net Income | -21.79 | -17.83 | -26.30-547.3% | 0.59 | -24.05 | -18.14-422.2% | 5.88 | -23.12 |
| Net Income From Continuing Operations | -21.79 | -17.83 | -26.30-547.3% | 0.59 | -24.05 | -18.14-422.2% | 5.88 | -23.12 |
| Net Income | -21.79 | -17.83 | -26.30-547.3% | 0.59 | -24.05 | -18.14-422.2% | 5.88 | -23.12 |
| EPS (Recurring) per share | -0.23 | -0.22 | -0.20-385.7% | 0.05 | -0.24 | -0.19 | 0.07 | -0.20 |
| EPS (Basic, Before Extraordinaries) per share | -0.22 | -0.18 | -0.26-425.0% | 0.01 | -0.24 | -0.18-325.0% | 0.08 | -0.23 |
| EPS (Diluted) per share | -0.22 | -0.18 | -0.26-425.0% | 0.01 | -0.24 | -0.18-460.0% | 0.08 | -0.23 |
| EBITDA | -21.04 | -22.55 | -13.73 | 10.86 | -6.50 | -11.06 | -7.20 | -8.10 |
| Non-Operating Income (Expense) | 1.77 | 3.72 | 1.12-94.0% | 1.86 | -11.62-234.2% | -3.44-182.3% | 18.59 | -6.19-196.1% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.71+76.3% | 1.39+90.4% | 1.69+156.1% | 1.20+179.1% | 0.97+56.5% | 0.73+12.3% | 0.66-80.8% | 0.43 |
| Price To Sales Ratio ratio | 5.35 | 4.68 | 6.65 | 3.85 | 2.71 | 2.61 | 3.13 | 7.29 |
| Gross Margin % | 15.62 | 21.50 | 50.92 | 85.76 | 70.00 | 53.73 | 54.16 | 70.86 |
| Operating Margin % | -487.40 | -467.39 | -181.22 | 16.76 | -68.36 | -149.97 | -102.88 | -78.99 |
| Net Margin % | -417.27 | -307.51 | -253.13 | 1.67 | -141.92 | -170.14 | 46.57 | -142.32 |
| Shares Outstanding million shares | 100.70+0.4% | 100.60+0.3% | 100.34+0.2% | 100.33+0.2% | 100.33+0.2% | 100.29+39.8% | 100.09+39.5% | 100.09+80.1% |
| Market Capitalization | 96.19-12.5% | 229.27+156.5% | 485.57+274.2% | 205.47+34.4% | 109.94-18.4% | 89.40-53.0% | 129.77-41.3% | 152.84+74.0% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 208.66-19.8% | 260.31+27.7% | 203.81+108.6% | 97.70-47.5% | 186.13-30.6% | 268.24-25.7% | 360.91-20.1% | 451.89+52.2% | 296.98 |
| Short Term Receivables | 25.32+9.9% | 23.04-0.4% | 23.13+31.6% | 17.57-43.5% | 31.07+61.9% | 19.19+25.5% | 15.29-30.7% | 22.07+50.2% | 14.69 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.61-44.5% | 2.90+935.7% | 0.28+12.0% | 0.25 |
| Other Current Assets | 2.26-39.4% | 3.73-38.4% | 6.06-10.5% | 6.77-17.6% | 8.22-68.8% | 26.32+111.9% | 12.42-7.4% | 13.41+18.7% | 11.30 |
| Total Current Assets | 236.24-17.7% | 287.07+23.2% | 233.00+90.9% | 122.04-45.9% | 225.43-28.5% | 315.36-19.5% | 391.52-19.7% | 487.64+50.9% | 323.22 |
| Net Property, Plant & Equipment | 62.45-17.7% | 75.86-18.2% | 92.74-14.1% | 107.90-27.2% | 148.27+1.9% | 145.52+109.9% | 69.32+590.4% | 10.04+38.9% | 7.23 |
| Total Investments and Advances | 3.29-39.3% | 5.42-31.0% | 7.85-10.7% | 8.79+34.8% | 6.52-7.0% | 7.01+27.0% | 5.52+192.1% | 1.89+89.0% | 1.00 |
| Long-Term Note Receivable | 1.80-14.3% | 2.10 | - | - | - | - | - | - | - |
| Intangible Assets | 0.54-51.8% | 1.12+67.2% | 0.67-6.9% | 0.72-61.1% | 1.85+17.1% | 1.58+42.3% | 1.11-12.6% | 1.27-11.2% | 1.43 |
| Deferred Tax Assets | 7.14-24.0% | 9.39 | - | - | - | - | - | - | - |
| Other Assets | 20.02+72.7% | 11.59 | 0.00-100.0% | 21.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 331.48-15.6% | 392.55+17.4% | 334.27+28.0% | 261.22-31.6% | 382.08-18.6% | 469.47+0.4% | 467.47-6.7% | 500.84+50.5% | 332.88 |
| Short Term Debt Incl. Current Port. of LT Debt | 18.16-25.9% | 24.52+79.5% | 13.66+6.4% | 12.84+21.4% | 10.58+57.9% | 6.70+526.2% | 1.07+224.2% | 0.33+1550.0% | 0.02 |
| Accounts Payable | 17.28-7.4% | 18.66-2.1% | 19.07-11.1% | 21.46-9.7% | 23.76-3.5% | 24.61-15.9% | 29.26+84.3% | 15.88+67.9% | 9.46 |
| Other Current Liabilities | 110.31-10.4% | 123.09+0.6% | 122.41+785.1% | 13.83-7.9% | 15.01-27.5% | 20.71-35.8% | 32.27+5.3% | 30.65-14.8% | 35.97 |
| Total Current Liabilities | 145.75-12.3% | 166.27+7.2% | 155.14+222.3% | 48.13-2.5% | 49.35-5.1% | 52.02-16.9% | 62.60+33.6% | 46.87+3.1% | 45.45 |
| Long Term Debt | 101.74+19.5% | 85.13+7.5% | 79.19+25.8% | 62.93-30.3% | 90.30-9.7% | 99.98+114.8% | 46.54+4462.7% | 1.02+10100.0% | 0.01 |
| Provision for Risks Charges | 1.33+19.8% | 1.11-49.5% | 2.20-7.9% | 2.39-41.3% | 4.07+1.5% | 4.01+40.7% | 2.85+6.3% | 2.68-21.9% | 3.43 |
| Deferred Tax Liabilities | 6.76-25.0% | 9.01+5531.3% | 0.16 | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00-100.0% | 12.88-41.0% | 21.83+1055.0% | 1.89-59.1% | 4.62 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 255.58-2.3% | 261.52+4.8% | 249.57+84.5% | 135.28-7.1% | 145.60-9.4% | 160.62+43.4% | 112.00+121.5% | 50.57+3.4% | 48.90 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 75.90-42.1% | 131.03+54.7% | 84.69-28.2% | 117.97-46.7% | 221.29-19.7% | 275.57-12.6% | 315.12-23.0% | 409.30+54.5% | 264.87 |
| Total Shareholders Equity | 75.90-42.1% | 131.03+54.7% | 84.69-28.2% | 117.97-46.7% | 221.29-19.7% | 275.57-12.6% | 315.12-23.0% | 409.30+54.5% | 264.87 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00-100.0% | 7.97-47.5% | 15.18-54.4% | 33.27-17.5% | 40.35-1.5% | 40.97+114.4% | 19.11 |
| Total Equity | 75.90-42.1% | 131.03+54.7% | 84.69-32.8% | 125.94-46.7% | 236.47-23.4% | 308.85-13.1% | 355.47-21.1% | 450.27+58.6% | 283.98 |
| Total Liabilities & Stockholders Equity | 331.48-15.6% | 392.55+17.4% | 334.27+28.0% | 261.22-31.6% | 382.08-18.6% | 469.47+0.4% | 467.47-6.7% | 500.84+50.5% | 332.88 |
| Book Value Per Share per share | 0.76-42.0% | 1.31+11.0% | 1.18-54.3% | 2.58-47.0% | 4.87-24.4% | 6.44-13.2% | 7.42-23.1% | 9.65+30.9% | 7.37 |
| Tangible Book Value Per Share per share | 0.75-42.3% | 1.30+11.1% | 1.17-54.5% | 2.57-46.7% | 4.82-24.7% | 6.40-13.4% | 7.39-23.2% | 9.62+31.2% | 7.33 |
| Full-Time Employees people | 229+3.2% | 222+0.5% | 221-6.8% | 237-19.4% | 294+4.6% | 281+6.4% | 264+54.4% | 171+26.7% | 135 |
| Price to Book Ratio ratio | 3.26 | 1.39 | 2.25 | 0.70 | 1.67 | 4.20 | 2.31 | 1.73 | 3.70 |
| Return on Assets % | -18.73 | -10.10 | -36.82 | -28.24 | -20.13 | -17.42 | -21.08 | -18.86 | -30.22 |
| Return on Equity % | -65.53 | -34.02 | -108.18 | -53.55 | -34.50 | -27.63 | -28.18 | -23.25 | -37.33 |
| Return on Invested Capital % | -38.17 | -16.98 | -61.76 | -58.71 | -36.59 | -21.73 | -28.22 | -19.16 | -37.90 |
| Quick Ratio ratio | 1.62 | 1.73 | 1.50 | 2.54 | 4.57 | 6.03 | 6.21 | 10.40 | 7.11 |
| Current Ratio ratio | 1.62 | 1.73 | 1.50 | 2.54 | 4.57 | 6.06 | 6.25 | 10.40 | 7.11 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -65.23 | -67.80 | -36.70 | -108.61 | -114.10 | -124.91 | -98.13 | -115.19 | -88.24 |
| Depreciation | 19.05 | 20.12+1.6% | 19.81+6.8% | 18.55+0.5% | 18.45+30.6% | 14.13+43.0% | 9.88+43.8% | 6.87+189.9% | 2.37 |
| Other Funds (Non Cash) | 20.52 | 49.26 | -14.58-191.1% | 16.01+18.2% | 13.55-25.9% | 18.29-37.8% | 29.42+6.8% | 27.54+2.4% | 26.89 |
| Funds from Operations | -25.66 | 1.58 | -31.47 | -74.05 | -82.10 | -92.49 | -58.82 | -80.78 | -58.98 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -16.34 | -41.72-177.9% | 53.57+9.5% | 48.93 | -5.73 | -12.28 | -21.97-288.6% | 11.65 | -9.09 |
| Cash from Operating Activities | -42.00 | -40.14-281.6% | 22.10 | -25.12 | -87.82 | -104.77 | -80.79 | -69.13 | -68.06 |
| Capital Expenditures | -3.36 | -3.54 | -3.84 | -1.07 | -2.44 | -18.53 | -46.57 | -12.96 | -4.88 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | -1.64 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.05-87.8% | 0.41-67.5% | 1.26 |
| Purchase or Sale of Investments | 35.22 | -26.03 | -98.79 | -12.89-10015.4% | 0.13-99.1% | 14.83 | -8.19 | -23.32-159.5% | 39.20 |
| Purchase of Investments | -115.88 | -160.27 | -162.48 | -13.38 | 0.00 | -0.14 | -8.19 | -23.32 | - |
| Sale Or Maturity of Investments | 151.11 | 134.24+110.8% | 63.69+12898.0% | 0.49+276.9% | 0.13-99.1% | 14.98 | - | - | 39.20 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00-100.0% | 0.08 | 0.00-100.0% | 10.96 | 0.00 | 0.00 | - |
| Cash from Investing Activities | 31.87 | -29.58 | -102.63 | -15.53 | -2.76-138.0% | 7.27 | -54.70 | -35.87-200.8% | 35.58 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.25 | 0.04-100.0% | 82.68+21.5% | 68.04 | -0.57-101.0% | 56.15+471.8% | 9.82 | -0.47-100.2% | 236.37 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.47 | 0.00 |
| Sale of Common Pref Stock | 0.25 | 0.04-100.0% | 82.68+21.5% | 68.04 | -0.57-101.0% | 56.15+471.8% | 9.82 | 0.00-100.0% | 236.37 |
| Proceedsfrom Stock Options | 0.25 | 0.04-100.0% | 82.68+21.5% | 68.04 | -0.57-101.0% | 56.15+505.7% | 9.27 | 0.00-100.0% | 236.37 |
| Issuance or Reduction of Debt, Net | - | -5.40-129.7% | 18.17-26.1% | 24.60+457.8% | 4.41 | 0.00-100.0% | 24.33 | 0.00 | -0.13 |
| Change in Long Term Debt | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00-100.0% | 1.78-79.4% | 8.65+277.7% | 2.29 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -16.10 | -16.20-118.0% | 89.80+7.8% | 83.33+5530.4% | 1.48-96.9% | 47.82+73.9% | 27.50 | -3.86-101.6% | 236.24 |
| Exchange Rate Effect | 2.41 | 3.94 | -2.75-409.0% | 0.89 | -3.36 | -5.74-172.1% | 7.96 | -2.10 | -8.85 |
| Net Change in Cash | -23.83 | -81.97-1355.3% | 6.53-85.0% | 43.56 | -92.47 | -55.43 | -100.03 | -110.96-156.9% | 194.91 |
| Free Cash Flow | -44.18 | -42.50-317.7% | 19.52 | -26.19 | -90.26 | -123.28 | -126.79 | -82.04 | -72.77 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow ratio | - | - | 8.35 | - | - | - | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 166.85-15.8% | 185.66-23.8% | 208.66-19.8% | 192.22-26.3% | 198.15-27.4% | 243.69+14.4% | 260.31+27.7% | 260.95+287.4% |
| Short Term Receivables | 13.64-53.6% | 15.05-41.0% | 25.32+9.9% | 26.41-5.3% | 29.37+11.5% | 25.52-36.8% | 23.04-0.4% | 27.88+26.9% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.93+26.0% | 3.84+47.1% | 2.26-39.4% | 2.56-54.4% | 3.12-53.0% | 2.61-43.0% | 3.73-38.4% | 5.61-21.6% |
| Total Current Assets | 184.42-20.0% | 204.55-24.7% | 236.24-17.7% | 221.19-24.9% | 230.64-24.6% | 271.82+5.3% | 287.07+23.2% | 294.43+205.1% |
| Net Property, Plant & Equipment | 53.99-23.1% | 57.93-20.6% | 62.45-17.7% | 66.71-17.8% | 70.17-16.5% | 72.93-17.0% | 75.86-18.2% | 81.18-15.4% |
| Total Investments and Advances | 4.72-86.7% | 3.84-11.3% | 3.29-39.3% | 35.74+431.8% | 35.49+414.3% | 4.33-45.0% | 5.42-31.0% | 6.72-59.6% |
| Intangible Assets | 1.12-2.6% | 0.22-8.3% | 0.54-51.8% | 0.84+21.7% | 1.15+76.9% | 0.24-64.7% | 1.12+67.2% | 0.69+4.5% |
| Deferred Tax Assets | 0.380.0% | 0.380.0% | 7.14-24.0% | 0.38-52.5% | 0.38 | 0.38 | 9.39 | 0.80 |
| Other Assets | 22.73+40.9% | 22.26+54.9% | 20.02+72.7% | 18.18+50.9% | 16.13+65.4% | 14.37 | 11.59 | 12.05 |
| Total Assets | 267.37-24.5% | 289.19-20.6% | 331.48-15.6% | 343.05-13.3% | 353.97-13.1% | 364.09+2.7% | 392.55+17.4% | 395.88+88.8% |
| Short Term Debt Incl. Current Port. of LT Debt | 14.27-44.5% | 15.16-38.5% | 18.16-25.9% | 26.57+91.7% | 25.71+90.7% | 24.65+83.3% | 24.52+79.5% | 13.86+4.5% |
| Accounts Payable | 18.20+3.9% | 17.09-0.7% | 17.28-7.4% | 16.10-13.0% | 17.52-3.8% | 17.21+7.2% | 18.66-2.1% | 18.51-9.6% |
| Income Tax Payable | - | - | - | - | - | - | - | 0.14 |
| Other Current Liabilities | 102.48-17.5% | 102.25-15.3% | 110.31-10.4% | 105.91-20.5% | 124.20-2.8% | 120.71-6.3% | 123.09+0.6% | 133.14+1202.7% |
| Total Current Liabilities | 134.96-19.4% | 134.50-17.3% | 145.75-12.3% | 148.58-10.3% | 167.43+4.9% | 162.57+2.6% | 166.27+7.2% | 165.65+276.9% |
| Long Term Debt | 90.01+2.1% | 93.44+11.0% | 101.74+19.5% | 92.65-5.7% | 88.12-8.9% | 84.17-7.1% | 85.13+7.5% | 98.26+12.9% |
| Provision for Risks Charges | 1.33+2.3% | 1.32+15.8% | 1.33+19.8% | 1.34-44.9% | 1.30-40.6% | 1.14-49.1% | 1.11-49.5% | 2.43-5.1% |
| Deferred Tax Liabilities | - | - | 6.76-25.0% | - | - | - | 9.01+5531.3% | 0.12 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00 |
| Total Liabilities | 226.30-11.9% | 229.27-7.5% | 255.58-2.3% | 242.57-9.0% | 256.86-0.6% | 247.88-6.1% | 261.52+4.8% | 266.45+99.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 41.07-57.7% | 59.92-48.4% | 75.90-42.1% | 100.48-22.4% | 97.11-34.7% | 116.20+28.3% | 131.03+54.7% | 129.42+70.0% |
| Total Shareholders Equity | 41.07-57.7% | 59.92-48.4% | 75.90-42.1% | 100.48-22.4% | 97.11-34.7% | 116.20+28.3% | 131.03+54.7% | 129.42+70.0% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 41.07-57.7% | 59.92-48.4% | 75.90-42.1% | 100.48-22.4% | 97.11-34.7% | 116.20+28.3% | 131.03+54.7% | 129.42+70.0% |
| Total Liabilities & Stockholders Equity | 267.37-24.5% | 289.19-20.6% | 331.48-15.6% | 343.05-13.3% | 353.97-13.1% | 364.09+2.7% | 392.55+17.4% | 395.88+88.8% |
| Book Value Per Share per share | 0.41-57.7% | 0.60-48.3% | 0.76-42.0% | 1.00-22.5% | 0.97-34.5% | 1.16-7.9% | 1.31+11.0% | 1.29-5.8% |
| Tangible Book Value Per Share per share | 0.40-58.3% | 0.59-49.1% | 0.75-42.3% | 0.99-23.3% | 0.96-35.1% | 1.16-7.2% | 1.30+11.1% | 1.29-5.1% |
| Full-Time Employees people | - | - | 229+3.2% | - | - | - | 222+0.5% | - |
| Price to Book Ratio ratio | 3.26 | 4.19 | 4.83 | 2.94 | 1.32 | 0.95 | 1.39 | 1.64 |
| Return on Assets % | -21.03 | -20.69 | -18.76 | -9.67 | -15.62 | -16.88 | -10.14 | -34.64 |
| Return on Equity % | -94.56 | -76.76 | -65.63 | -31.08 | -48.38 | -58.64 | -34.17 | -102.06 |
| Return on Invested Capital % | -16.62 | -11.63 | -14.80 | 0.30 | -12.99 | -9.05 | 2.72 | -10.16 |
| Quick Ratio ratio | 1.37 | 1.52 | 1.62 | 1.49 | 1.38 | 1.67 | 1.73 | 1.78 |
| Current Ratio ratio | 1.37 | 1.52 | 1.62 | 1.49 | 1.38 | 1.67 | 1.73 | 1.78 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -21.79 | -17.83 | -26.36-545.3% | 0.75 | -24.07 | -18.13-421.5% | 5.92 | -23.06 |
| Depreciation | 4.40-13.7% | 4.55-7.7% | 5.10-12.5% | 4.99+5.7% | 5.10+7.8% | 4.93+7.9% | 5.83+12.5% | 4.72+5.6% |
| Other Funds (Non Cash) | 1.95-90.6% | -2.89-140.7% | 12.12 | 9.34-41.6% | 20.70+79.2% | 7.10 | -17.28-185.4% | 15.98 |
| Funds from Operations | -15.44-992.5% | -16.17 | -9.14 | 15.09 | 1.73 | -6.09 | -5.53 | -2.36 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.09 | 0.61 | -1.34-125.5% | -16.71 | -12.45-120.4% | -11.22 | 5.26-91.1% | -3.71-608.2% |
| Cash from Operating Activities | -14.34 | -15.56 | -10.47 | -1.63 | -10.72-120.6% | -17.31 | -0.26-100.7% | -6.07 |
| Capital Expenditures | -0.25 | -0.27 | -0.49 | -2.35 | -0.31 | -0.40 | -1.74 | -0.84 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00 | 0.00 | 0.04+100.0% |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 19.00 | -5.92-228.1% | 23.06 | -0.92-104.0% | -52.79 | 4.62 | -14.92 | 23.14 |
| Purchase of Investments | -27.70 | -78.28 | -7.06 | -2.85-134.0% | -145.33 | -5.04 | -63.97 | 8.38 |
| Sale Or Maturity of Investments | 46.70-49.5% | 72.36+649.8% | 30.12-38.6% | 1.93-86.9% | 92.54 | 9.65 | 49.05 | 14.76 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 18.75 | -6.19-246.7% | 22.57 | -3.27-114.6% | -53.11 | 4.22 | -16.66 | 22.33 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.17 | 0.03 | 0.04 | 0.00 | 0.00-100.0% | 0.00 | -0.00-100.0% | 0.00-100.0% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.17 | 0.03 | 0.04 | 0.00 | 0.00-100.0% | 0.00 | -0.00-100.0% | 0.00-100.0% |
| Proceedsfrom Stock Options | 0.17 | 0.03 | 0.04 | 0.00 | 0.00-100.0% | 0.00 | -0.00-100.0% | 0.00-100.0% |
| Issuance or Reduction of Debt, Net | -1.39 | -1.40 | -1.39-123.8% | -1.38 | -1.37 | -1.25-108.4% | 5.84+5209.1% | -1.22-127.2% |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -3.16 | -4.83 | -4.03-228.3% | -4.09 | -4.14-105.3% | -3.94-132.5% | 3.14-92.5% | -3.98-326.1% |
| Exchange Rate Effect | -0.43 | -0.22-115.6% | 1.34 | 1.71 | -0.52-128.7% | 1.41 | -2.06-220.5% | -2.24 |
| Net Change in Cash | 0.82 | -26.79 | 9.41 | -7.27-172.3% | -68.50-362.8% | -15.62 | -15.84-122.8% | 10.05 |
| Free Cash Flow | -14.59 | -15.82 | -10.95 | -2.81 | -11.04-121.7% | -17.71 | -0.81-102.1% | -6.85 |
| Price to Free Cash Flow ratio | - | - | - | - | - | 4.85 | 6.63 | 3.55 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Biological Products, (No Diagnostic Substances) | 41.51 | 72.95 | +75.8% | 100.0% |
| Total | 41.51 | 72.95 | +75.8% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| France | 41.51 | 72.95 | +75.8% | 100.0% |
| Total | 41.51 | 72.95 | +75.8% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.48% | 0.3M | 69.5M | 104.80K |
| 2026-10-15 | 0.46% | 0.3M | 69.5M | 85.11K |
| 2026-09-30 | 0.51% | 0.4M | 69.5M | 74.74K |
| 2026-09-15 | 0.70% | 0.5M | 69.5M | 52.02K |
| 2026-08-31 | 0.42% | 0.3M | 69.5M | 27.72K |
| 2026-08-14 | 0.43% | 0.3M | 69.5M | 31.27K |
| 2026-07-31 | 0.43% | 0.3M | 69.5M | 31.15K |
| 2026-07-15 | 0.42% | 0.3M | 69.5M | 33.35K |
| 2026-06-30 | 0.46% | 0.3M | 69.5M | 39.24K |
| 2026-06-15 | 0.53% | 0.4M | 69.5M | 39.55K |
| 2026-05-29 | 0.51% | 0.4M | 69.5M | 40.89K |
| 2026-05-15 | 0.49% | 0.3M | 69.5M | 39.06K |
| 2026-04-30 | 0.52% | 0.4M | 69.5M | 43.03K |
| 2026-04-15 | 0.55% | 0.4M | 69.5M | 45.28K |
| 2026-03-31 | 0.52% | 0.4M | 69.5M | 45.31K |
| 2026-03-13 | 0.50% | 0.4M | 69.5M | 59.07K |
| 2026-02-27 | 0.56% | 0.4M | 69.5M | 66.56K |
| 2026-02-13 | 0.57% | 0.4M | 69.5M | 90.47K |
| 2026-01-30 | 0.57% | 0.4M | 69.5M | 95.44K |
| 2026-01-15 | 0.60% | 0.4M | 69.5M | 121.12K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.00 | 0.55 | 2.60 | 9.455 | 1.00 | 0.00 | 0.629 | -0.044 | 0.001 |
| call | 5.00 | 0.00 | 0.75 | 0.25 | 6.999 | 15.00 | 0.00 | 0.261 | -0.028 | 0.001 |
| call | 7.50 | 0.00 | 4.20 | 0.00 | 14.261 | 0.00 | 0.00 | 0.586 | -0.069 | 0.001 |
| put | 2.50 | 0.00 | 4.00 | 0.55 | 0.000 | 1.00 | 0.00 | -0.362 | -0.048 | 0.001 |
| put | 5.00 | 3.60 | 4.20 | 2.00 | 12.774 | 11.00 | 0.00 | -0.399 | -0.062 | 0.001 |
| put | 7.50 | 4.30 | 8.50 | 0.00 | 0.000 | 0.00 | 0.00 | -0.414 | -0.068 | 0.001 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-12 | SEC |
| 2026-11-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-12 | SEC |
| 2026-11-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-09 | SEC |
| 2026-11-09 | SCHEDULE 13D/A | SEC | ||
| 2026-10-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-27 | SEC |
| 2026-09-14 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-14 | SEC |
| 2026-09-11 | 6-K/A | 2026-06-30 | SEC | |
| 2026-09-11 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-11 | SEC |
| 2026-09-01 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-01 | SEC |
| 2026-08-06 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-06 | SEC |
| 2026-08-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-06 | SEC |
| 2026-07-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-30 | SEC |
| 2026-06-26 | 6-K/A | 2026-06-26 | SEC | |
| 2026-06-25 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-25 | SEC |
| 2026-06-25 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-25 | SEC |
| 2026-06-11 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-11 | SEC |
| 2026-06-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-09 | SEC |
| 2026-05-21 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-20 | SEC |
| 2026-05-20 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-20 | SEC |
| 2026-05-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-12 | SEC |
| 2026-05-11 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-11 | SEC |
| 2026-05-11 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-11 | SEC |
| 2026-05-04 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-04 | SEC |
| 2026-04-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-27 | SEC |
| 2026-04-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-13 | SEC |
| 2026-03-20 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2025-12-31 | SEC |
| 2026-03-20 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-19 | SEC |
| 2026-03-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-12 | SEC |
| 2026-01-08 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-01-08 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| B Group, Inc. | 4.54% |
| Long Focus Capital Management, LLC | 3.79% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.66% |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.31% |
| BlackRock, Inc. | 0.31% |
| LPL Financial LLC | 0.12% |
| MORGAN STANLEY | 0.12% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% |
| UBS Group AG | 0.07% |
| BNP PARIBAS FINANCIAL MARKETS | 0.05% |
Funds
| Fund | % owned |
|---|---|
| Nomura Healthcare Fund | 0.31% |
| iShares Biotechnology ETF | 0.31% |
| Fidelity Nasdaq Composite Index Fund | 0.00% |
OakChart. CLLS. Cached 15 minutes. Terms
Some panels did not load: insider.